Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirzotamab clezutoclax - AbbVie

Next Previous
Drug Profile

Mirzotamab clezutoclax - AbbVie

Alternative Names: ABBV-155; Mirzotamab-AbbVie

Latest Information Update: 26 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Developer AbbVie; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Bcl-X protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioblastoma; Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 12 Sep 2025 AbbVie completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in US, Australia, Canada, Israel, Japan, the Netherlands, Puerto Rico, Spain, South Korea and Taiwan (IV) (NCT03595059)
  • 07 Dec 2024 Preclinical trials in Acute myeloid leukaemia in USA (IV), prior to December 2024
  • 07 Dec 2024 Pharmacodynamics and adverse event data from a preclinical trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top